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Abstract: Systemic sclerosis (SSc) is a lethal disease that is characterized by auto-immunity, vascular
injury, and progressive fibrosis of multiple organ systems. Despite the fact that the exact etiology
of SSc remains unknown, oxidative stress has been associated with a large range of SSc-related
complications. In addition to the well-known detrimental properties of reactive oxygen species (ROS),
gasotransmitters (e.g., nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S)) are
also thought to play an important role in SSc. Accordingly, the diverse physiologic actions of NO and
CO and their role in SSc have been previously studied. Recently, multiple studies have also shown
the importance of the third gasotransmitter H2S in both vascular physiology and pathophysiology.
Interestingly, homocysteine (which is converted into H2S through the transsulfuration pathway)
is often found to be elevated in SSc patients; suggesting defects in the transsulfuration pathway.
Hydrogen sulfide, which is known to have several effects, including a strong antioxidant and
vasodilator effect, could potentially play a prominent role in the initiation and progression of
vasculopathy. A better understanding of the actions of gasotransmitters, like H2S, in the development
of SSc-related vasculopathy, could help to create early interventions to attenuate the disease course.
This paper will review the role of H2S in vascular (patho-)physiology and potential disturbances
in SSc. Moreover, current data from experimental animal studies will be reviewed. Lastly, we will
evaluate potential interventional strategies.
Keywords: gasotransmitters; systemic sclerosis; vasculopathy; endothelial injury; therapeutic intervention
1. Introduction
Systemic sclerosis (SSc) is a severe progressive fibrotic connective tissue disease that often affects
multiple systems [1,2]. The disease is characterized by chronic inflammation, autoimmunity, and
vasculopathy, which all lead to substantial disability, high morbidity and mortality rates, and a
decreased quality of life [3]. Reported prevalence rates for SSc range from 30 to 300 cases per 1 million
persons, and the age of onset is approximately 50 years [4–6]. A variety of disabling complications
(e.g., skin fibrosis, gastrointestinal dysmotility, scleroderma renal crisis (SRC), and lung involvement)
occur in the early stages of the disease. Despite many efforts, the pathogenesis still remains unknown
and effective disease-modifying treatment is currently unavailable. In addition, current treatment
options (such as immunosuppressants) can cause a variety of adverse effects, including bone marrow
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depression, impaired hepatic and renal function, and infections. Therefore, new (low-risk) therapy
options need to be found.
Endothelial dysfunction is a main event in the pathogenesis of SSc [7], and the vascular bed is a
major target for immune-inflammatory injury. The vascular injury (i.e., vasculopathy) is characterized by
thedysfunction of endothelial cells (ECs), inflammation, and vascular wall remodeling [8]. Raynaud’s
phenomenon (RP), which manifests as episodic vasospastic events leading to the discoloration of the
extremities, is the most recognizable and primary clinical sign that reflects the vascular injury [9].
Raynaud’s phenomenon often precedes visceral disease by several years and, therefore, RP is a crucial
part of the important criteria for the diagnosis of early SSc (VEDOSS criteria) [2]. Following RP, the
vasculopathy often progresses and becomes clinically evident as necrotic lesions of the fingertips
(i.e., digital ulcerations), SRC, and pulmonary arterial hypertension (PAH) [2]. A current hypothesis
is that early detection of SSc may allow an adequate start of appropriate therapeutic regimen to arrest
disease progression.
The exact etiology of SSc remains unknown, but some studies have suggested that gasotransmitters
play an important role in its pathogenesis. Gasotransmitters, which are endogenously produced gaseous
signaling molecules, play a major role in several physiological processes, ranging from vessel tone
regulation, modulation of the immune system, and protection against oxidative stress [10,11]. To date,
three main gasotransmitters have been discovered, namely, hydrogen sulfide (H2S), carbon monoxide
(CO), and nitric oxide (NO) [12]. As these gases perform critical roles, a deviation of their normal level
may be associated with the occurrence of several diseases ranging from neurodegenerative diseases
to auto-immune diseases. Interestingly, some reports have stated that SSc patients show a decreased
level of H2S. Moreover, the beneficial effects of H2S in a scleroderma-like experimental animal study
have also been proven. Therefore, an assessment of the role played by H2S in SSc-related vasculopathy
could lead to a better understanding of this disease, which could subsequently help to create early
interventions to attenuate the disease course. This review focuses on the role of H2S the pathogenesis
of SSc-related vasculopathy in relation to its functional properties in the healthy vascular system.
Furthermore, we evaluate the effects of H2S-based therapeutic interventions.
2. Role of Nitric Oxide and Carbon Monoxide in Systemic Sclerosis
The role of NO in SSc has been extensively discussed elsewhere [13–18], and, therefore, will
be shortly mentioned here. The free radical gas NO is synthesized from the amino acid L-arginine
by a family of isoenzymes, termed nitric oxide synthases (NOS) [19,20]. There are three known
isoforms, namely endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS).
Endothelial NOS is the major isoform regulating vascular function, and it is primarily expressed
in ECs, cardiomyocytes, neurons, and hepatocytes [21]. Induction of iNOS occurs usually in response
to infection and chronic inflammation [22], and it is especially found in immunological cells, such as
macrophages and neutrophils [23,24]. Nitric oxide may stimulate soluble guanylyl cyclase (sGC) in
vascular smooth muscle cells (VSMCs) to induce the formation of cyclic guanosine monophosphate
(cGMP) [25,26]. Subsequently, the formation of cGMP activates protein kinase G (PKG) [26], which
leads to the reduction of cytosolic Ca2+ and reduction of the sensitivity of smooth muscle cells (SMCs) to
Ca2+. As a result of this process, the intracellular concentration of calcium decreases and vasorelaxation
is promoted [11,27,28]. Endothelial dysfunction is believed to be a main target in SSc. Although several
mechanisms have been proposed that play an important role in this process, the exact role of NO
still remains incompletely understood as both protective and harmful effect of NO have previously
been described [13]. It was previously suggested that a decreased release of NO, which may lead to
impaired endothelial-dependent vasodilatation, might play an important role in the pathogenesis of the
SSc-related vasculopathy. In support, several studies reported a decreased level of NO release [29,30].
Subsequently, this may promote the development of vasculopathy by inducing recurrent RP attacks,
increasing vascular wall thickness, and by enhancing the platelet aggregation. Moreover, NO is also
believed to protect the endothelium from oxidative stress by acting as a free radical scavenger, and
Int. J. Mol. Sci. 2018, 19, 4121 3 of 21
inhibiting lipid peroxidation [31,32]. In contrast, NO is also believed to have several harmful effects.
For instance, it was previously reported that iNOS expression, which is often considered as a harmful
enzyme [33], is up-regulated in affected skin, fibroblast, and endothelial cells [14,34]. Interestingly, it
has been proposed that with the progression of SSc the NO production, which is primarily produced by
eNOS in the early stages of the disease, is replaced by iNOS in endothelial cells and fibroblast [14,34].
This finding may indicate that the increased levels of NO, which were previously reported in SSc [35],
may be induced by the increased expression of mainly iNOS. These conflicting results indicate that
the exact role of NO in SSc still remains complex, and further studies should be conducted in order to
clarify the role of NO in the pathogenesis of SSc.
Although the role of CO in SSc is less known, previous studies have suggested that CO may play
an important role in several vascular diseases with a similar pathology as SSc. Carbon monoxide is
generated by haem oxygenases (HO), namely HO-1 and HO-2, which are both expressed in the heart
and blood vessels, as a result of the degradation of haem [36,37]. The oxidative degradation of haem,
catalyzed by HO, results in the formation of iron (Fe2+), CO, and biliverdin [27]. Biliverdin is further
converted into biologically important antioxidant bilirubin. Comparable to the formation of NO, this
reaction requires O2 and nicotinamide adenine dinucleotide phosphate (NADPH) as cofactors. Similar
to NO, CO is also thought to have important vasoregulatory effects. For instance, CO is thought to
induce vasorelaxation in large vessels (e.g., aorta) by activating sGC in VSMCs, which leads to the
formation of cGMP [27]. In smaller vessels, CO is thought to promote vasorelaxation by affecting
calcium-activated potassium channels in VSMCs [38]. In contrast to these findings, other studies
failed to demonstrate the vasodilatory effect of CO on cerebral arteries [39,40], or even reported on
the vasoconstricting effect of CO [41], presumably by negatively affecting eNOS activity [28,42].
In addition to its vasoregulatory effect, CO is also believed to have several anti-inflammatory,
anti-apoptotic, and pro-apoptotic effects. For instance, it was previously shown that CO may act as an
anti-apoptotic agent in ECs, and, thus, prevent cell injury through AKt activation, and by affecting
p38 mitogen-activated protein kinases (MAPK) signaling pathway [43–45]. In contrast, CO can also
arrest fibroblast proliferation [46] as well as VSMC proliferation [47]. Considerable evidence supports
a protective role for the HO-1/CO system in several cardiovascular diseases (e.g., atherosclerosis,
myocardial infarction, and hypertension). The protective effect of CO in these diseases is thought
to be associated with the prevention of oxidative stress-induced endothelial damage [43], increased
production of bilirubin [48], increased stability of HIF-1α [49], and improved vasorelaxation [38].
Given the fact that some of these diseases may share a common pathogenesis, it could be postulated
that CO might also have several beneficial effects in SSc patients.
3. The Role of Hydrogen Sulfide in Vascular Biology
3.1. Production of H2S
Hydrogen sulfide is an evolutionary gaseous signaling molecule, and the earliest forms of life on
earth depended on sulfur as an energy source and not oxygen. Only at the time that oxygen levels
started to rise on earth, sulfide syntrophy largely disappeared. It was not until the last couple of decades
that H2S was rediscovered in mammalians as being an endogenously produced gasotransmitter, and
its important functions have now been increasingly recognized [50]. Although high concentrations
of H2S are believed to be toxic, the enhancement of its physiological effects has been proven to be
beneficial in several diseases.
This endogenous gasotransmitter is enzymatically generated by four enzymes, namely
cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), cysteine aminotransferase (CAT), in
conjunction with 3-mercaptopyruvate sulfurtransferase (3MST) [51–54]. These H2S producing enzymes
are expressed in various vascular cell types (e.g., ECs and vascular smooth muscle cells (VSMCs)).
Both CBS and CSE are found in the cytosol, whereas 3MST is mainly found in the mitochondria [55].
In ECs, CSE activity, which is strictly regulated by intracellular Ca2+ concentrations, is the main
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contributor to H2S production [56]. Both of the pyridoxal-5 phosphate-dependent enzymes (i.e., CSE
and CBS) play an important role in the transsulfuration pathway [55,57]. During this process,
homocysteine is converted into cystathionine by CBS, which is then converted by CSE to L-cysteine
(Figure 1). Ammonium and pyruvate are also produced during this process. However, their exact
roles in cellular functions remain not well clarified [58]. Although CSE, CBS, 3MST, and CAT are
essential for the formation of H2S, it should be realized that these enzymes are also responsible for
a number of other reactions that do not lead to the production of H2S [57]. Although H2S can also
be produced through several non-enzymatic processes (e.g., through reductive chemistry of various
forms of sulfur, including thiosulfate, thiocystine, and sulfite), these pathways are less well understood
and only account for a small portion of H2S production [59].
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Hydrogen sulfide can be quickly eliminated and it is initially oxidized to thiosulfate. Following
this process, thiosulfate is further converted into sulfite and sulfate (Figure 1). Other routes of
elimination include binding to methemoglobin and cytosolic methylation [65]. Given the fact that
thiosulfate can easily be converted back into H2S, this sodium salt is often considered as a H2S donor.
Sulfate is considered an important end-product of H2S metabolism. In humans, the majority of the
circulatory inorganic sulfate is generated from the sulfur containing amino acids (SAA) methionine and
cysteine, which are both derived from dietary protein [66,67]. However, because of the beneficial effects
of H2S, it can also be hypothesized that the higher intake of SAAs contributes to the formation of H2S,
and thereby, beneficially influences the cardiovascular profile, and, as a result, patient survival [68,69].
Therefore, sulfate levels could also possibly serve as an indication of H2S production. However, in
order to understand the role of this important gasotransmitter in pathophysiology of many vascular
diseases (including SSc), one has to comprehend the role that it plays in normal vascular biology.
3.2. Vascular Biology
3.2.1. Vascular Tone Regulation
Regulation of the vascular tone is crucial in maintaining adequate blood flow and tissue
oxygenation to the organs. This balance in vasodilation and vasoconstriction is strictly regulated by
various factors, among which H2S plays an important role. Hydrogen sulfide is believed to have a
biphasic effect on the vascular tone, through the mediation of both vasoconstriction and vasodilation.
Lower concentrations of H2S are believed to induce vasoconstriction. This postulation is supported
by the fact that the reversal of the vasodilatory effect of acetylcholine and histamine, which are
both NO-dependent vasodilators, was achieved after treatment with H2S in lower concentrations
(<100 µM) [70]. In addition, even very low concentrations of 30 µM were found to induce a strong
vasoconstrictive effect. This vasoconstrictive effect is believed to be induced through the inactivation
of NO, down-regulation of eNOS, increase in reactive oxygen species (ROS) production, and through
the decrease of intracellular cyclic adenosine monophosphate (cAMP) in VSMCs [54,71]. Moreover, it
was previously demonstrated that the vasoconstrictive effect of H2S was endothelial dependent in
phenylephrine-precontracted rat aorta [72]. This experimental study demonstrated that the contractile
effect of H2S disappeared after the removal of the endothelium. Interestingly, the contractile activity of
H2S was found to be more prominent in the absence of oxygen [73].
Conversely, higher levels are believed to promote vasodilation by affecting KATP channels, Ca2+
channels, and the Cl−/HCO3− exchanger (Figure 2). In particular, H2S leads to the hyperpolarization
of KATP channels in VSMCs, which reduces intracellular Ca2+ and leads to the relaxation of smooth
muscle cells [74]. However, given the fact that glibenclamide, which is a KATP inhibitor, only
partially prevented vasodilation, it has to be noted that the vasodilatory effect of H2S is not solely
exerted through its effect on the KATP channels [75]. In addition, H2S also induces vasodilation by
modulating Kv7 channels in VSMCs [75], and by affecting KCa channels [76]. Moreover, the inhibition of
cytochrome c oxidase by H2S may lead to a decrease in cellular ATP levels and activate KATP channels,
which subsequently promotes vasodilation [77,78]. In contrast to the vasoconstrictive effect of H2S,
vasodilation is thought to be promoted by the activation of eNOS and stimulation of NO-release [79].
In addition, it has been shown that the intermediates that form due to the NO-H2S crosstalk might
also play an important role in this process. Hydrogen sulfide has been proven to reduce the blood
pressure in various experimental models. More particularly, several experimental animal studies in
mice have shown a reduction of the blood pressure after the administration of both systemic and local
H2S donors (e.g., NaHS) [80–82]. More recently, it has been reported that H2S and NO, which are
both key regulators in various physiological functions, are able to interact with each other and form
intermediates with important physiological functions [83]. For instance, H2S was found to reduce
oxidized NO forms, and thereby form several intermediate products (e.g., SSNO−, HSNO, HNO, and
HSSH), which are highly redox-sensitive [83]. Therefore, it has become increasingly clear that the
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interactions between NO and H2S may have a significant effect on the regulation of the vascular tone.
In support, Hosoki et al. (1997) demonstrated that H2S can induce a stronger vasorelaxant effect in
the presence of an NO donor [84]. Another study reported that HNO might induce vasodilation by
activating the cGMP-dependent pathway [85]. A recent review describes these interactions between
gasotransmitters in the redox system as the “redox signaling interactome”, and these interactions may
lead to targets for new therapeutic interventions [86].
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Figure 2. Physiological effects of intracellular hydrogen sulfide production in vascular smooth muscle
cells and endothelial cells. Vascular endothelial growth factor receptor 2 (VEGFR-2); Acetylcholine
receptor (AchR); Cysteine (Cys); endothelial nitric oxide synthases (eNOS); black solid arrows represent
a direct effect, the black dotted arrows represent a direct effect on a different cell, and the green T-bar
represents the inhibitory effect of hydrogen sulfide.
3.2.2. Cell Proliferation and Angiogenesis
Hydrogen sulfide was previously reported to stimulate EC proliferation, which is an essential
part of the initial angiogenic response. Two independent studies reported that H2S, in various
concentration (ranging from 1–600 µM), increased the proliferation of human umbilical vein endothelial
cells (HUVECs) and of transformed endothelial cells by 30–100% [87,88]. Moreover, H2S, at low
concentrations (10–20 µmol/L), promotes EC migration and adhesion, which may further stimulate
angiogenesis. Regarding the angiogenic properties of H2S, Cai and colleagues (2007) reported that
intraperitoneal administration of an H2S donor (NaHS, 10–20 µmol per kg/day for seven days)
increased neovascularization in a mouse model [87]. However, higher concentrations of this H2S donor
in the same assay failed to demonstrate this angiogenic property. This difference might be due to
the bell-shaped biological dose-response, with lower doses having a cytoprotective effect, whereas a
higher dosage might have a more pronounced cytotoxic effect [89,90].
There are several intracellular signaling pathways that play an important role in the pro-angiogenic
effect of H2S. For instance, vascular endothelial growth factor (VEGF) plays a significant role in the
angiogenesis, both in physiology and pathophysiology [91]. Moreover, it has previously been reported
that VEGF promotes H2S synthesis, presumably through calcium/calmodulin-dependent activation of
CSE [92]. Other important signaling pathways include the phosphatidylinositol 3-kinase–Akt–survivin
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pathway, the extracellular signal-regulated kinase, and p38 pathways [93]. In addition, there is some
evidence supporting the role of NO in this process [94], however, its exact implication in disease must be
further investigated.
3.2.3. Antioxidant Effect of H2S
Hydrogen sulfide, in low concentrations, is believed to have a strong antioxidant capacity, which
is mainly due to its ROS inhibiting and scavenging property. However, studies on its antioxidant
mechanism are limited. Evidence exists indicating that H2S up-regulates glutathione (GSH) and
increases the expression of antioxidant enzymes, such as glutathione peroxidase and superoxide
dismutase [95–97]. In addition, H2S was reported to increase intracellular thioredoxin (Trx-1).
This multifunctional molecule not only has ROS scavenging properties, but also plays an important
role in cell proliferation [98], apoptosis [99], and gene expression [100]. More recently, increasing
evidence revealed that the transcription factor nuclear factor like 2 (Nrf2) may regulate the antioxidant
capacity of H2S by promoting cellular antioxidant gene expression (e.g., glutamate cysteine ligase
regulatory subunit, glutamate cysteine ligase catalytic subunit) [101]. This transcription factor can also
increase the expression of glutathione reductase, which promotes the recycling of GSH and increases
GSH/GSSG ratio, and thereby, reduces oxidative stress [102].
4. The Potential Role of H2S in the Development of Systemic Sclerosis-Related Vasculopathy
4.1. Link between H2S and Vascular Injury
The vascular endothelium is considered to be a major target for pathological processes in SSc [7].
Damage to the endothelium is characterized by EC apoptosis, vascular endothelial permeability,
and impairment of cell–cell adhesion, which may lead to alterations in EC signal transduction [103].
Collectively, this may lead to endothelial dysfunction, subsequently causing an impaired relaxation of the
vessels. Patients often present with RP as the earliest manifestation of this endothelial dysfunction [104].
Homocysteine (Hcy), which is converted into H2S through the transsulfuration pathway, is
considered to be a potential mediator in the initiation of endothelial dysfunction in SSc. It was previously
reported that increased levels of Hcy are associated with a higher risk of several cardiovascular diseases,
including atherosclerosis, renal, and cerebrovascular diseases [105]. Interestingly, Hcy is also found to be
elevated in SSc patients [106–108]. The exact reason for this elevation is unknown. Although the causal
relationship between genetic abnormalities and the development of SSc has never been demonstrated, it
could be hypothesized that the elevated levels of Hcy may be caused by a defect in the transsulfuration
pathway. For instance, Hankey et al. (1999) stated that the most common enzyme defect associated
with moderately raised homocysteine level is a point mutation in the coding region of the gene for
methylenetetrahydrofolate reductase (MTHFR) [109]. Szamosi et al. (2009) aimed to investigate the
prevalence of the MTHFR gene polymorphism in SSc patients [110]. Although they did not demonstrate
any differences in Hcy level and MTHFR genotypes, as compared to healthy controls, they did observe
significantly higher levels of Hcy in patients with macroangiopathy. Therefore, they concluded that
Hcy levels might be associated with the occurrence/development of SSc-related vasculopathy.
Moreover, elevated levels of Hcy can also be caused by a reduced vitamin intake or vitamin deficiency
(e.g., folate, vitamin B12, vitamin B6) [111]. This defect could lead to a decreased production of H2S.
A previously conducted experimental animal study in CBS deficient mice showed that cbs+/− mice had a
normal mean lifespan, and only developed a mild increase in plasma Hcy levels [112]. Moreover, other
studies reported that cbs+/− and cbs−/− mice demonstrate endothelial dysfunction in both large and
smaller vessels [113,114]. Hcy is believed to induce an oxidative milieu by stimulating the production
of ROS (by the up-regulation of nicotinamide adenine dinucleotide phosphate) [115], and inhibiting
antioxidant enzymes (including intracellular glutathione peroxidase) [116–118]. These superoxide anions
may react with NO, which leads to the formation of peroxynitrite and a decreased bioavailability
of NO, which may further impair the endothelial function [119]. The endothelial dysfunction in
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experimental animal studies can be largely attributed to the increase in oxidative stress and decrease
of NO bioavailability. In addition, higher levels of Hcy may also lead to a decrease in H2S production,
which is believed to be caused by a decrease in CSE activity. This decrease in CSE activity was previously
demonstrated in an experimental animal study in which homocysteine at higher levels reduced CSE
activity in rat liver [120]. Moreover, Chang et al. (2008) reported that, although cardiac CSE mRNA
expression was up-regulated in the HHcy rats, CSE activity was inhibited by 50% [121]. Furthermore,
the administration of H2S in this animal study slightly lowered Hcy level, decreased myocardial lipid
peroxidation, and reduced ROS generation. The decrease in CSE activity may further increase the
susceptibility to endothelial injury in SSc patients. The importance of Hcy in the development and
perpetuation of endothelial injury is also supported by Caramaschi et al. (2007). They not only observed
a higher level of Hcy in SSc patients, as compared to healthy controls, but also demonstrated that the
plasma concentration of Hcy is strongly associated with nailfold videocapillaroscopy (NVC) patterns,
which is commonly used to assess SSc specific microvascular lesions (Figure 3) [106,122]. This relationship
was found to be irrespective of age, RP, SSc duration, the severity of skin involvement and folate levels.
These findings are further supported by the observations of Motegi et al. (2014), stating that the plasma
concentration of Hyc increases with the progression of nailfold abnormalities [123]. These observations
may suggest that even mildly increased levels of Hcy may cause vascular damage in SSc through the
direct effect of Hcy on the endothelium, and its inhibitory effect on H2S production. However, future
studies are needed in order to clarify the exact role of Hcy in the occurrence of SSc-related vasculopathy.
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These conflicting observations underline the complexity of the role that is played by H2S in hypoxic
conditions. Hydrogen sulfide is also believed to down-regulate hypoxia-inducible factor 1-alpha
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(HIF-1α) protein levels in cultured cells under hypoxic conditions [128]. This inhibitory effect was
achieved with 100µM of sodium hydrosulfide (NaHS) or 10µM of sodium sulfide (Na2S).
Vascular injury in SSc may also be the result of impaired angiogenesis. Increasing evidence
suggests that an imbalance of pro-angiogenic and anti-angiogenic mediators may be responsible
for the impaired angiogenesis [129]. A previously conducted study demonstrated that ECs isolated
from SSc patients show an impaired response to VEGF [130]. Hydrogen sulfide is believed to play a
significant role in the essential components of the angiogenic response, including the proliferation
and migration of endothelial cells. Two studies reported that H2S leads to an increase of 20% in
the proliferation of transformed endothelial cells, and 100% increase in HUVEC cells, in addition
to a 30% increase in mitigation in transformed endothelial cells and a six-fold increase in HUVEC
cells [88,93]. The pathways that are involved in these processes have been studied, and H2S was
found to activate PI-3K/Akt axis, enhance the phosphorylation of MAPK pathway, and induce hsp27
phosphorylation [87,88]. Furthermore, it is thought that KATP-channel opening, more particularly K+
efflux, can promote EC motility [88]. In addition, it was previously demonstrated that VEGF increases
the production of H2S, which may subsequently lead to VEGF-induced and H2S-induced EC migration.
A current hypothesis is that both VEGF and H2S-induced EC migration involve the same downstream
pathways, and this assumption is supported by Papapetropoulos et al. (2009), who reported that
“VEGF-induced angiogenesis was suppressed in aortic rings of CSE-deficient mice” [88].
4.2. Link between H2S and Inflammation
Endogenously synthesized H2S is believed to be an important mediator of inflammation [131],
and therefore may play an important role in the pathogenesis of SSc-related vasculopathy. Current
literature has provided some conflicting results on the exact role of H2S in the inflammatory process.
For instance, H2S is thought to have both pro-inflammatory and anti-inflammatory effects. This is
presumably due to the biphasic effect of H2S, with low concentrations inhibiting inflammation and
higher concentrations inducing inflammation. The pro-inflammatory effect is thought to be induced
by the activation of adenosine triphosphate (ATP)-sensitive K+ channels, and this was previously
observed in mice with septic shock [132]. The administration of a CSE inhibitor, which decreases
the H2S level, was shown to increase survival in this experimental study [132]. Moreover, in an
experimental animal study, Zanardo et al. (2006) demonstrated that H2S donors inhibit leukocyte
adherence during vascular inflammation, which further supports the anti-inflammatory effects of
H2S [133]. In another experimental animal study, the administration of H2S donors, such as NaSH,
was found to induce inflammation through the up-regulation of nuclear factor-kappa B (NF-κB) and
extracellular-signal-regulated kinase (ERK) 1/2 signaling [134]. Furthermore, Rinaldi et al. (2006)
found that H2S prevented apoptosis of human granulocytes via the inhibition of p38 mitogen-activated
protein kinases and caspase 3 [135]. Conversely, H2S is also thought to have several anti-inflammatory
effects, including free radical scavenging properties (e.g., peroxynitrite), inhibition of leukocyte
adherence to the endothelium [133], and H2S is believed to reduce the leukocyte infiltration [136,137].
4.3. Link between H2S and Fibrosis
Hyperhomocysteinemia might be a contributing factor in the increased production of collagen in
SSc patients [138]. Hyperhomocysteinemia-induced oxidative stress is thought to be a key player in this
process. During this process, matrix metallo-proteinases (MMPs) are believed to be activated, which
subsequently cause disturbances in the metabolism of extracellular matrix (ECM). Moreover, Hcy is
believed to lead to vascular stiffness by regulating the elastin/collagen ratio [139]. As increased levels
of Hcy are known to decrease the CSE activity, it could be postulated that hyperhomocysteinemia leads
to a decreased production of H2S, which may further sustain the pro-fibrotic state [121]. Conversely,
hydrogen sulfide itself is believed to have several anti-fibrotic effects. For instance, H2S is thought
to inhibit myofibroblast activation, which is a key event in the pathogenesis of fibrosis in SSc [140].
In addition, the anti-inflammatory effect of H2S (e.g., decreasing the expression of inflammatory
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cytokines) is also thought to block/reduce the disease-related pro-fibrotic state. Wang and colleagues
demonstrated that NaHS, which is an H2S donor, inhibits the fibroblast differentiation and attenuates
the protein expressions of TGF-β1 [141]. In support, several others have concluded “that organ
fibrosis might be associated with H2S deficiency” [142,143]. The blockage of TGF-B1-induced fibroblast
differentiation is presumably achieved through the inhibition of the phosphorylation of Smad3 and
mitogen-activated protein kinases [144]. Furthermore, ROS are also thought to play a crucial role
in the formation of fibrosis in SSc patients [8]. Hydrogen sulfide has been demonstrated to have
ROS-scavenging properties, and thereby eliminates the fibrosis-inducing properties of ROS. Moreover,
it was previously shown that the administration of an H2S donor can lead to the increased expression
of antioxidant enzymes (e.g., manganese superoxide dismutase, catalase, and copper-zinc superoxide
dismutase), which reduces the oxidative milieu [145]. These findings are further supporting the
suggestion that H2S might play a pivotal role in the pathogenesis of SSc-related vasculopathy.
5. Hydrogen Sulfide as a Therapeutic Option
Exogenous alterations of H2S levels can be done in several ways, including, but not limited to,
treatment with sulfide-sodium salts, exposure to gaseous H2S, slow-releasing H2S donors, and by
improving the endogenously produced H2S (e.g., up-regulating the expression of H2S-producing
enzymes) [146]. It was not until the last couple of decades that the perception of H2S shifted and
its important functions were recognized. Following this shift in perception, multiple studies have
demonstrated the cytoprotective effects of H2S [136,137]. In particular, some have demonstrated that
H2S, in relatively low concentrations, can up-regulate endogenous antioxidant systems, increase the
production of cAMP, and can up-regulate anti-inflammatory and cytoprotective genes [147]. In contrast
to lower concentrations, a higher concentration of H2S is believed to be cytotoxic, which is likely due
to its ability to inhibit cytochrome c oxidase. The inhibition of cytochrome c oxidase in complex V
leads to a decrease in ATP production, and in the presence of oxygen it may lead to the formation of
ROS [148]. Moreover, the generation of ROS, glutathione depletion, and the induction of mitochondrial
cell death pathways may also enhance or even induce an oxidative milieu [149]. Although studies in
SSc patients are lacking, several experimental animal and human studies in other vascular conditions
have clearly demonstrated the beneficial effect of H2S treatment [74,150–152].
5.1. Hydrogen Sulfide in Experimental Animal Studies
Sulfide salts (e.g., Na2S and NaHS) have previously been used in numerous studies and demonstrated
to have protective effects in a variety of diseases, including I/R-related diseases [153]. For instance,
Zhang et al. (2013) demonstrated that preconditioning with NaHS reduced the I/R-induced hepatic
injury in mice. They stated that the protective effect was presumably achieved by the inhibition of
mitochondrial permeability transition pore (mPTP) opening [154]. Johansen et al. (2006) were the
first to demonstrate the cytoprotective effect of H2S following myocardial I/R injury [155]. They
reported that NaHS treatment (1 µM) 10 min prior to reperfusion led to a reduction of the infarct
size of 20%. Following their results, several others reported supporting results. For instance, in a
recently conducted study, researchers found that injection with Na2S (compared to vehicle) prior to the
ischemia limited the extent of myocardial damage following I/R [156]. Moreover, they demonstrated
that this sulfide salt reduced oxidative stress and apoptosis, increased the nuclear accumulation of
Nrf2, increased the expression of Trx1 and HO-1, and activated the PKCε-p44/42-STAT-3 pro-survival
signaling pathway [156]. Comparable results were found when NaHS was injected one day prior to
the myocardial infarction (MI) [157]. NaHS not only reduced the myocardial infarct size, but also
prevented apoptosis of cardiomyocyte. However, NaSH that was administered five days prior to MI
had no effect.
It was previously proposed that H2S might also have beneficial effects in renal IR injury.
A previously conducted study demonstrated that topical treatment of NaHS on the kidneys 15 min
prior to ischemia significantly increased the kidney function [158]. Another study reported that,
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during I/R, the renal injury is caused by a reduction in the CBS activity [159]. This finding may
suggest that H2S may be hampered during I/R injury. Furthermore, subtoxic concentrations of H2S
can induce a hibernation-like state in mice [160,161]. It was previously reported that mice, treated
with gaseous hydrogen sulfide, showed a reduction of >90% in metabolic rate, and a decline in core
body temperature to near ambient temperature. Moreover, H2S is also known to modulate the blood
pressure, and, therefore, it may serve as an add-on treatment option in hypertension. In various
experimental mice models, H2S was found to reduce the arterial pressure after systemic treatment with
NaHS [162,163] or after local treatment [164]. These findings are supported by Huang et al. (2015), they
stated that NaHS reduced systolic pressure in Dahl rats with high salt-induced hypertension [165].
It has become increasingly clear that H2S is also abundantly produced by gut microbiota through
sulfate-reducing bacteria. Sulfate-reducing bacteria are a non-enzymatic source of H2S, and several
bacteria (e.g., E. coli, Salmonella, and Enterobacter) are known to have the ability to produce H2S [166].
It was previously shown that antibiotic treatment aimed at reducing the intestinal microbiota resulted
in a significant reduction of thiosulfate levels [167]. This finding sheds light on sulfate-reducing
bacteria as a therapeutic target in various vascular diseases [166].
The only SSc-resembling experimental animal study was conducted by Wang and colleagues
(2016), who investigated the effect of NaHS (56 and 112 µg/kg) in an experimental scleroderma-like
animal study in mice [141]. They demonstrated that the plasma H2S levels were decreased in mice after
injection with bleomycin. Moreover, they stated that H2S exerts an anti-inflammatory effect by the
reduction of macrophage recruitment in lung tissues. In addition, they also stated that NaHS attenuates
the protein expressions of TGF-β1, indicating that H2S also inhibits the fibroblast differentiation and
extracellular matrix production. In support, several others have concluded “that organ fibrosis might
be associated with H2S deficiency” [142,143]. These findings are further supporting the suggestion
that H2S can be seen as a promising treatment option in SSc. The hypothetical effects of H2S treatment
in SSc can be seen in Figure 4.
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5.2. Hydrogen Sulfide in Human Studies
Despite the fact that several experimental animal studies clearly demonstrated the beneficial
effects of treatment with sulfide salts, large studies in humans are still lacking. Thereby, the majority of
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H2S-releasing derivatives are not yet used in clinical settings. However, sodium thiosulfate (STS) is the
exception, given the fact that this sodium salt is already used in various diseases. For instance, STS is a
well-known effective antidote that is used in cyanide intoxication. Moreover, STS was proven to be
beneficial as a treatment of cisplatin-induced hearing loss. For instance, an open-label, randomized
trial demonstrated that hearing loss was significantly lower in children that were treated with STS,
as compared to the control group [168]. Importantly, they also reported that the use of STS was
not associated with the occurrence of serious adverse events. Sodium thiosulfate is also used in
calciphylaxis in patients with end-stage renal disease [169]. Calciphylaxis is a rare disorder that is
characterized by calcification of the tunica media, and it is often associated with high mortality rates.
Calciphylaxis is a dreaded complication and it often leads to the ulceration of the extremities and
contributes to the development of peripheral arterial disease [170]. This dreaded complication can also
occur in SSc and it remains virtually untreatable. Several studies have shown that STS has beneficial
effects on cutaneous lesions, with a potentially long-lasting effect (11 months–3 years) [171]. In a
multi-centric study of 27 calciphylaxis patients that were treated with STS, 70% of these patients had a
complete or partial response [172]. Although these effects are presumably mediated through different
pathways as compared to the effects as hypothesized in SSc, these promising results indicate that STS
can be safely used in the clinical setting. In our hospital, STS is already in a Phase III clinical trial that is
designed to evaluate the effect of sodium thiosulfate compared with placebo treatment, in adjunction
to optimal reperfusion therapy for acute MI, on left ventricular ejection fraction.
6. Conclusions
Vasculopathy is the hallmark of SSc and it often leads to severe disability and morbidity. To date,
SSc is still associated with increased mortality rates given the fact that effective disease-modifying
treatment options are currently unavailable. Hydrogen sulfide donors have previously been proven to
have beneficial effects in a variety of diseases. These effects range from ROS scavenging, anti-fibrotic,
pro-angiogenic, to vasoactive properties. Although the pathways that are involved in H2S production
have not been clearly investigated in SSc, current data may suggest that the readily available H2S-donor
STS may have a great therapeutic potential. Moreover, given the abundant experience in other
diseases, with minimal adverse events reported, this drug could probably be safely administered in
SSc. A current hypothesis is that early treatment of SSc with STS may alter or even arrest disease
progression. Although future studies are needed in order to investigate this hypothesis, the promising
effects of H2S-based therapeutic targets may encourage further study in SSc.
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